• Telehealth
• FDA
• Compounding
• Legal

FDA's 30 telehealth warning letters (March 3, 2026): what the agency said was misleading

By Peptide Policy Watch staff · Published November 6, 2026 · 5 min read · 3 sources, 3 checked at the source

On March 3, 2026, FDA announced it had sent 30 warning letters to telehealth companies over compounded GLP-1 marketing on their websites. The release is short. The useful part is what FDA named as the primary violations — and what it repeated about compounded drugs versus generics and approved products.

Facts are as of November 6, 2026. Sources, with retrieval dates, are at the bottom. This page summarizes FDA's press release and related FDA telehealth guidance; it is not a roster of the 30 recipients.

What the March 3 release announced

FDA's press announcement is dated March 3, 2026. [V] In it, the agency says it sent 30 warning letters after reviewing telehealth websites that, in FDA's view, made false or misleading statements about compounded GLP-1 products. [V]

Commissioner Marty Makary is quoted saying the agency is paying close attention to misleading claims by telehealth and pharma companies "across all media platforms," and that while compounded drugs can matter for shortages or unique patient needs, compounders "should not try to compound drugs in a way that circumvents FDA's approval process." [V]

FDA called this the second wave of telehealth letters since a September push against misleading consumer-facing drug ads, and it said the prior six months produced more such letters than the whole decade before. [V]

Those volume claims are FDA's own description of its enforcement pace. This page does not independently audit that count. [U]

The two primary violation themes FDA named

FDA's release is specific about what it saw as the main problems in those letters: [V]

1. Sameness claims — wording that treats a compounded preparation as if it were identical to an approved medicine.
2. Obscured sourcing / branding — putting the telehealth company's own name or mark on the product presentation without clear qualification, so a reader might assume that company compounded it.

Those two themes match the longer list on FDA's telehealth promotion page, which also flags calling a compounded drug a "generic," claiming FDA approval or evaluation, saying a compounded product is clinically proven to match the approved drug, and describing a pharmacy as FDA-approved or FDA-licensed. [V]

Compounded vs generic vs approved — FDA's reminder in the same release

The March 3 announcement closes the loop the same way FDA's compounding Q&A does: a compounded preparation has not cleared FDA's premarket review for safety, effectiveness or quality. [V] Generics are different: they do receive FDA approval. [V]

That distinction shows up constantly in telehealth ads. Our GLP-1 approved vs compounded vs research-labeled explainer sorts the three lanes, and our telehealth clinics explainer collects the broader FDA/FTC framing without naming clinics to use.

What a warning letter is (and isn't)

A warning letter is an FDA enforcement communication about specific conduct the agency has reviewed — here, website claims. It is not a court judgment, not a product recall by itself, and not proof of how any individual patient's medicine performed. FDA's release does not reprint the 30 letters or list every recipient by name. [U]

To find letters, FDA's telehealth promotion page tells readers to search the warning-letter database for "telehealth." [V] We are not linking individual company storefronts from this page.

How this sits next to later telehealth stories

March 3, 2026 is one date on a longer calendar. Industry self-regulation has also weighed in on compounded tirzepatide ads; our NAD / Good Life decision brief covers a November 4, 2026 advertising challenge. Separately, some telehealth companies now advertise access to branded self-pay GLP-1s through their own pharmacies — a different lane from the compounded marketing FDA targeted in March. See the LifeMD / Lilly self-pay brief. Congress has its own pending answer on cross-state compounders: the SAFE Drugs Act, S.3794, which would add reporting and a not-FDA-approved label. Our weekly roundup for November 2 to 8 puts these telehealth moves side by side.

Limits

We summarize FDA's March 3 press release and the related telehealth promotion page. We did not open all 30 individual warning letters for this brief. [U] Recipient lists, response letters and any later closings belong in those primary letter files when you need them. Nothing here is medical advice, dosing guidance or a recommendation of any clinic or pharmacy.

Sources (retrieved November 6, 2026)

1. FDA, "FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s," March 3, 2026 [V] — https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s
2. FDA, "FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs" [V] — https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs
3. FDA, "Compounding and the FDA: Questions and Answers" [V] — https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

Spot a mistake? See how we source and our corrections policy.

Image: AI-generated. Image credits